Commercial sterile injectable manufacturing is not only a production activity. It is a patient safety commitment, a quality system test, and a supply continuity challenge happening at the same time. For pharma and biotech leaders, the most visible consequence of […]
Sterile injectable fill-finish is where CMC either protects patients and timelines, or quietly accumulates risk until it becomes a deviation, an investigation, or a regulatory delay. When we outsource to a European CDMO, the documentation set has to do two […]
When an injectable solution is administered, it bypasses the patient’s normal protective barriers. Skin and the digestive system no longer act as filters. At that point, the primary packaging becomes the barrier. That is the starting point for any sterility […]
Contents Phase 1: Define Your Programme Requirements Phase 2: Due Diligence and Capability Screening Phase 3: Site Qualification and GMP Auditing Phase 4: Assemble the Technical Data Package Phase 5: Stakeholder Governance and Programme Management Phase 6: Technology Transfer from […]
To audit a sterile fill-finish Contract Development and Manufacturing Organisation (CDMO) effectively in 2026, assess nine core areas: quality management systems, contamination control strategy, facility and equipment qualification, technology transfer capability, data integrity controls, analytical and stability services, supply chain […]
How Overall Equipment Effectiveness Predicts Pre-Filled Syringe Capacity at a CDMO Overall Equipment Effectiveness (OEE) is the most reliable indicator of a Contract Development and Manufacturing Organisation’s (CDMO) true available capacity for pre-filled syringe fill-finish. It combines three measurable factors, […]
Get notified on our latest news.
